Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.96
- Piotroski Score 3.00
- Grade Buy
- Symbol (PHAT)
- Company Phathom Pharmaceuticals, Inc.
- Price $9.33
- Changes Percentage (-1.27%)
- Change -$0.12
- Day Low $8.97
- Day High $9.98
- Year High $19.71
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $27.00
- High Stock Price Target $35.00
- Low Stock Price Target $12.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.46
- Trailing P/E Ratio -2.38
- Forward P/E Ratio -2.38
- P/E Growth -2.38
- Net Income $-201,592,000
Income Statement
Quarterly
Annual
Latest News of PHAT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MMI's robotic technology to support lymphatic surgery at TGH
Tampa General Hospital and the University of South Florida are introducing the world's most precise robotic surgical technology, the Symani system, to Florida through an agreement with Medical Microin...
By Yahoo! Finance | 4 days ago -
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia
Unicycive Therapeutics' application for approval of oxylanthanum carbonate to treat hyperphosphatemia in kidney disease patients on dialysis has been accepted by the FDA....
By MarketWatch | 1 week ago -
Breach hat-trick fires nine-try England to emphatic win against New Zealand
England defeated New Zealand 49-31 in WXV 1, with Dow and Kildunne scoring two tries each. England's impressive form raises questions about their dominance, especially after the Red Roses' 19th consec...
By The Guardian | 1 month ago
